Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ALEC |
---|---|---|
09:32 ET | 25629 | 4.08 |
09:33 ET | 4213 | 4.07 |
09:35 ET | 1858 | 4.085 |
09:37 ET | 2600 | 4.14 |
09:39 ET | 11100 | 4.14 |
09:42 ET | 1201 | 4.135 |
09:44 ET | 12990 | 4.09 |
09:46 ET | 10212 | 4.085 |
09:48 ET | 2025 | 4.1 |
09:50 ET | 200 | 4.11 |
09:51 ET | 3861 | 4.09 |
09:53 ET | 1903 | 4.065 |
09:55 ET | 1914 | 4.04 |
09:57 ET | 14293 | 4.03 |
10:00 ET | 2585 | 4.005 |
10:02 ET | 21404 | 4 |
10:04 ET | 15957 | 3.92 |
10:06 ET | 6385 | 3.97 |
10:08 ET | 3055 | 3.9982 |
10:09 ET | 2619 | 3.96 |
10:11 ET | 1689 | 3.99 |
10:13 ET | 5300 | 3.975 |
10:15 ET | 6773 | 3.975 |
10:18 ET | 5122 | 3.99 |
10:20 ET | 1250 | 3.965 |
10:22 ET | 5207 | 4.01 |
10:24 ET | 200 | 3.995 |
10:26 ET | 3158 | 4.005 |
10:27 ET | 1012 | 4.0001 |
10:29 ET | 14838 | 4.115 |
10:31 ET | 700 | 4.115 |
10:33 ET | 300 | 4.12 |
10:36 ET | 3566 | 4.11 |
10:38 ET | 1900 | 4.0801 |
10:40 ET | 1039 | 4.09 |
10:42 ET | 1400 | 4.1 |
10:44 ET | 2187 | 4.12 |
10:45 ET | 1600 | 4.11 |
10:47 ET | 2685 | 4.1 |
10:49 ET | 300 | 4.1 |
10:51 ET | 6500 | 4.115 |
10:54 ET | 400 | 4.115 |
10:56 ET | 1300 | 4.1 |
10:58 ET | 1923 | 4.1 |
11:00 ET | 1429 | 4.0947 |
11:02 ET | 2670 | 4.09 |
11:03 ET | 8112 | 4.1247 |
11:05 ET | 5045 | 4.04 |
11:07 ET | 2096 | 4.0301 |
11:09 ET | 3122 | 4.02 |
11:12 ET | 400 | 4.015 |
11:14 ET | 6819 | 4.0599 |
11:16 ET | 500 | 4.05 |
11:18 ET | 842 | 4.03 |
11:20 ET | 200 | 4.025 |
11:21 ET | 800 | 4.02 |
11:23 ET | 1080 | 4.02 |
11:27 ET | 945 | 3.985 |
11:30 ET | 600 | 3.98 |
11:32 ET | 2198 | 3.96 |
11:34 ET | 330 | 3.965 |
11:36 ET | 1818 | 3.94 |
11:38 ET | 300 | 3.94 |
11:39 ET | 700 | 3.93 |
11:43 ET | 992 | 3.92 |
11:45 ET | 300 | 3.925 |
11:48 ET | 5681 | 3.93 |
11:50 ET | 321 | 3.91 |
11:52 ET | 3087 | 3.88 |
11:54 ET | 5992 | 3.86 |
11:56 ET | 7700 | 3.83 |
11:57 ET | 1767 | 3.82 |
11:59 ET | 200 | 3.81 |
12:01 ET | 15183 | 3.782 |
12:03 ET | 851 | 3.79 |
12:06 ET | 4954 | 3.8 |
12:08 ET | 2532 | 3.795 |
12:10 ET | 36549 | 3.79 |
12:12 ET | 3441 | 3.8 |
12:14 ET | 8351 | 3.765 |
12:15 ET | 6451 | 3.735 |
12:17 ET | 854 | 3.74 |
12:19 ET | 3217 | 3.75 |
12:21 ET | 1105 | 3.7587 |
12:24 ET | 1000 | 3.79 |
12:26 ET | 402 | 3.78 |
12:28 ET | 334 | 3.79 |
12:30 ET | 6902 | 3.8 |
12:32 ET | 2417 | 3.8 |
12:33 ET | 200 | 3.8 |
12:35 ET | 4632 | 3.8426 |
12:37 ET | 2758 | 3.8442 |
12:39 ET | 2279 | 3.84 |
12:42 ET | 1000 | 3.84 |
12:44 ET | 6438 | 3.848 |
12:46 ET | 5119 | 3.8292 |
12:48 ET | 1134 | 3.8208 |
12:50 ET | 300 | 3.83 |
12:51 ET | 11052 | 3.83 |
12:53 ET | 491 | 3.83 |
12:55 ET | 8690 | 3.805 |
01:00 ET | 735 | 3.7954 |
01:02 ET | 1000 | 3.795 |
01:04 ET | 3893 | 3.795 |
01:06 ET | 2273 | 3.805 |
01:08 ET | 2896 | 3.785 |
01:09 ET | 908 | 3.785 |
01:11 ET | 2174 | 3.795 |
01:13 ET | 18836 | 3.79 |
01:15 ET | 1044 | 3.795 |
01:18 ET | 421 | 3.775 |
01:20 ET | 1717 | 3.79 |
01:22 ET | 1607 | 3.7999 |
01:24 ET | 700 | 3.795 |
01:26 ET | 300 | 3.795 |
01:27 ET | 7528 | 3.775 |
01:29 ET | 500 | 3.775 |
01:31 ET | 2646 | 3.765 |
01:33 ET | 1022 | 3.765 |
01:36 ET | 300 | 3.765 |
01:38 ET | 598 | 3.765 |
01:40 ET | 2709 | 3.76 |
01:42 ET | 222 | 3.76 |
01:44 ET | 400 | 3.76 |
01:45 ET | 8566 | 3.745 |
01:47 ET | 1664 | 3.74 |
01:49 ET | 5638 | 3.755 |
01:51 ET | 3965 | 3.785 |
01:54 ET | 1254 | 3.795 |
01:56 ET | 993 | 3.775 |
01:58 ET | 2251 | 3.7992 |
02:00 ET | 4332 | 3.805 |
02:02 ET | 1142 | 3.8 |
02:03 ET | 2301 | 3.7645 |
02:07 ET | 500 | 3.765 |
02:09 ET | 3246 | 3.755 |
02:12 ET | 500 | 3.7567 |
02:14 ET | 5931 | 3.735 |
02:16 ET | 938 | 3.735 |
02:18 ET | 7805 | 3.72 |
02:20 ET | 892 | 3.71 |
02:21 ET | 7371 | 3.7 |
02:23 ET | 3859 | 3.7001 |
02:25 ET | 337 | 3.705 |
02:27 ET | 286 | 3.705 |
02:30 ET | 4886 | 3.72 |
02:32 ET | 1553 | 3.71 |
02:34 ET | 400 | 3.71 |
02:36 ET | 2300 | 3.705 |
02:38 ET | 1771 | 3.715 |
02:39 ET | 2810 | 3.725 |
02:41 ET | 1600 | 3.73 |
02:43 ET | 100 | 3.73 |
02:45 ET | 557 | 3.74 |
02:48 ET | 4718 | 3.74 |
02:50 ET | 1100 | 3.74 |
02:52 ET | 800 | 3.725 |
02:54 ET | 2404 | 3.715 |
02:56 ET | 7322 | 3.7201 |
02:57 ET | 28530 | 3.74 |
02:59 ET | 1600 | 3.7461 |
03:01 ET | 1734 | 3.735 |
03:03 ET | 2630 | 3.7287 |
03:06 ET | 1199 | 3.7201 |
03:08 ET | 2877 | 3.735 |
03:10 ET | 12456 | 3.765 |
03:12 ET | 849 | 3.765 |
03:14 ET | 8900 | 3.765 |
03:15 ET | 6773 | 3.74 |
03:17 ET | 6879 | 3.7199 |
03:19 ET | 2746 | 3.73 |
03:21 ET | 1777 | 3.75 |
03:24 ET | 300 | 3.75 |
03:26 ET | 2219 | 3.745 |
03:28 ET | 13115 | 3.76 |
03:30 ET | 5240 | 3.755 |
03:32 ET | 100 | 3.755 |
03:33 ET | 1000 | 3.755 |
03:35 ET | 1300 | 3.755 |
03:37 ET | 5703 | 3.74 |
03:39 ET | 1650 | 3.7425 |
03:42 ET | 4175 | 3.745 |
03:44 ET | 300 | 3.745 |
03:46 ET | 6459 | 3.73 |
03:48 ET | 6444 | 3.725 |
03:50 ET | 7435 | 3.71 |
03:51 ET | 9113 | 3.715 |
03:53 ET | 11851 | 3.715 |
03:55 ET | 2247 | 3.715 |
03:57 ET | 6634 | 3.71 |
04:00 ET | 147874 | 3.76 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Alector Inc | 368.2M | -2.2x | --- |
Grail Inc | 470.4M | 0.0x | --- |
SAGE Therapeutics Inc | 292.4M | -0.9x | --- |
Regenxbio Inc | 502.9M | -2.0x | --- |
Y-mAbs Therapeutics Inc | 477.8M | -19.8x | --- |
Urogen Pharma Ltd | 465.9M | -3.5x | --- |
Alector, Inc. is a clinical-stage biotechnology company. The Company is focused on immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration diseases. The Company is engaged in developing therapies designed to counteract these pathologies simultaneously by restoring healthy immune function to the brain. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration and immunology to identify immune system. Its product candidates: latozinemab (AL001), AL002, and AL101, are in clinical development. Its immune-neurology product candidates are supported by biomarkers and seek to treat indications, including Alzheimer’s disease and genetically defined frontotemporal dementia patient populations. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $368.2M |
---|---|
Revenue (TTM) | $61.5M |
Shares Outstanding | 97.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.61 |
EPS | $-1.71 |
Book Value | $1.58 |
P/E Ratio | -2.2x |
Price/Sales (TTM) | 6.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -301.10% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.